Prosecution Insights
Last updated: April 19, 2026

Antecip Bioventures II LLC

7 pending office actions

Portfolio Summary

7
Total Pending OAs
4
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19270315 PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE TRAN, SUSAN T 1615 Final Rejection Jul 15, 2025
19258712 BUPROPION AS A MODULATOR OF DRUG ACTIVITY WEDDINGTON, KEVIN E 1629 Non-Final OA Jul 02, 2025
18601603 COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION RAMACHANDRAN, UMAMAHESWARI 1627 Final Rejection Mar 11, 2024
18179196 BUPROPION AS A MODULATOR OF DRUG ACTIVITY BARSKY, JARED 1628 Final Rejection Mar 06, 2023
18061091 BUPROPION AS A MODULATOR OF DRUG ACTIVITY VALENROD, YEVGENY 1628 Non-Final OA Dec 02, 2022
17571110 BUPROPION AS A MODULATOR OF DRUG ACTIVITY BARSKY, JARED 1628 Non-Final OA Jan 07, 2022
17541461 BUPROPION AS A MODULATOR OF DRUG ACTIVITY BARSKY, JARED 1628 Final Rejection Dec 03, 2021

Managing Antecip Bioventures II LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month